Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY PATIENT GROUP

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ADULTS

4.2.1. Market size and forecast

4.3. CHILDREN

4.3.1. Market size and forecast

Chapter: 5 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY DISTRIBUTION CHANNEL

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITAL PHARMACY

5.2.1. Market size and forecast

5.3. RETAIL PHARMACY

5.3.1. Market size and forecast

5.4. E-COMMERCE

5.4.1. Market size and forecast

Chapter: 6 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Naftifine Hydrochloride Ointment Market by Patient Group
6.2.5. North America Naftifine Hydrochloride Ointment Market by Distribution Channel

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Naftifine Hydrochloride Ointment Market by Patient Group
6.3.5. Europe Naftifine Hydrochloride Ointment Market by Distribution Channel

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Naftifine Hydrochloride Ointment Market by Patient Group
6.4.5. Asia-Pacific Naftifine Hydrochloride Ointment Market by Distribution Channel

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Naftifine Hydrochloride Ointment Market by Patient Group
6.5.5. LAMEA Naftifine Hydrochloride Ointment Market by Distribution Channel

Chapter: 7 COMPANY PROFILES

7.1. MERZ DERMATOLOGY

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. PARCHEM FINE & SPECIALTY CHEMICALS

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. LGM PHARMA

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. SEBELA PHARMACEUTICALS, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ERREGIERRE S.P.A

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. SIMAGCHEM CORPORATION

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. TARO PHARMACEUTICAL INDUSTRUES, LTD.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. RENAISSANCE PHARMA, INC.,

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. SHANGHAI YISA BIOTECHNOLOGY CO., LTD.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. SHAANXI TOP PHARM CHEMICAL CO., LTD.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments